Cala Health Inc.

Cala Health Inc. is a US-based company focused on developing innovative medical technology aimed at improving the quality of life for patients with movement disorders, particularly through its proprietary therapeutic devices. Founded in 2014 in San Mateo, US, Cala Health Inc. specializes in creating solutions for action hand tremors associated with essential tremor and Parkinson's disease.

The company has successfully raised a total of USD 50. 00 mn across various funding rounds, with its latest funding round bringing in USD 50. 00 mn from investors including Action Potential Venture Capital, Ascension Ventures, and Johnson & Johnson Innovation. In October 2025, Cala Health Inc.

raised an undisclosed amount of growth funding from new investor Venture Lab Niterra Group. The deal was part of a larger USD 50 million growth round. The company's CEO is Renee Ryan, and it was founded by Kate Rosenbluth, who has previously been involved in other ventures in the healthcare sector. Cala Health, Inc.

specializes in innovative medical technology, primarily through its flagship product, the Cala kIQ™ System. This FDA-cleared, wearable device employs Transcutaneous Afferent Patterned Stimulation (TAPS) Therapy to provide non-invasive treatment for action hand tremors associated with essential tremor and Parkinson's disease. The device is designed for on-demand therapy, enabling users to experience tremor reduction during a complete 40-minute session, with many users enjoying sustained relief lasting over an hour post-therapy. The company targets patients who struggle with the daily challenges posed by essential tremor, which affects millions of individuals worldwide, particularly in North America and Europe.

It serves a diverse clientele, including Medicare beneficiaries, veterans through the VA, and individuals purchasing directly from healthcare providers, reflecting a commitment to enhancing the quality of life for those impacted by this neurological condition. Cala Health generates revenue primarily through the sale of the Cala kIQ™ System and associated TAPS Therapy, which is reimbursed by Medicare and various commercial insurance plans. The company operates on a direct-to-consumer model, where users can obtain the device through prescriptions from healthcare providers who assess their hand tremors. The reimbursement structure allows for potential cost coverage, making the therapy accessible to a broader audience.

The company also collaborates with healthcare professionals to facilitate patient access to the system, which may include offering free trials depending on insurance coverage. Through this transaction framework, Cala Health aims to ensure that its innovative therapy reaches those who need it most, while also establishing a sustainable revenue stream. Cala Health Inc. plans to leverage recent funding to advance its product offerings and expand into new markets.

The company is focused on developing additional therapeutic devices to address various neurological disorders, with specific timelines for product launches to be announced in the near future. Furthermore, it aims to extend its reach into international markets, particularly targeting expansion in Europe and Asia by 2025. The funding received will be utilized to support research and development efforts, as well as to enhance marketing strategies to facilitate market entry.